Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Vanessa Torres-Llenza, Pooja Lakshmin & Daniel Z Lieberman. (2018) Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. Neuropsychiatric Disease and Treatment 14, pages 285-292.
Read now
Read now
İsmail Akaltun, Tayfun Kara & Hamza Ayaydın. (2018) A case of an 11-year-old girl diagnosed with OCD developing giggle incontinence following addition of aripiprazole to treatment. Psychiatry and Clinical Psychopharmacology 28:3, pages 343-345.
Read now
Read now
Eiji Kirino. (2014) Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolescent Health, Medicine and Therapeutics 5, pages 211-221.
Read now
Read now
Cüneyt Ünsal, Yakup Albayrak, Neslihan Albayrak, Murat Kuloglu & Kenji Hashimoto. (2013) Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatric Disease and Treatment 9, pages 1545-1552.
Read now
Read now
Peter Paul De Deyn, Annemieke FJ Drenth, Berry P Kremer, Richard C Oude Voshaar & Debby Van Dam. (2013)
Aripiprazole in the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy 14:4, pages 459-474.
Read now
Read now
Sushama Talegaonkar, Ashu Mittal, Shikha Parmar & Mohammed Aqil. (2009) Aripiprazole Loaded Polymeric Biodegradable Microspheres: Formulation and In Vitro Characterization. Journal of Dispersion Science and Technology 30:8, pages 1198-1202.
Read now
Read now
Martyn Wood & Charlie Reavill. (2007) Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opinion on Investigational Drugs 16:6, pages 771-775.
Read now
Read now
Arshia A. Shirzadi & S. Nassir Ghaemi. (2006) Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome. Harvard Review of Psychiatry 14:3, pages 152-164.
Read now
Read now
Yavuz S Silay & Joseph Jankovic. (2005) Emerging drugs in Tourette syndrome. Expert Opinion on Emerging Drugs 10:2, pages 365-380.
Read now
Read now
Robert M Post. (2005) Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database. Expert Opinion on Pharmacotherapy 6:4, pages 531-546.
Read now
Read now
Martin Lambert, Philippe Conus, Tim Lambert & Pat D McGorry. (2003) Pharmacotherapy of first-episode psychosis. Expert Opinion on Pharmacotherapy 4:5, pages 717-750.
Read now
Read now
Articles from other publishers (87)
Yunjuan Gao, Chengzhao Wu, Xingran Zhai, Ming Niu, Zhaofang Bai, Haibo Song, Xu Zhao, Jiabo Wang & Xiaohe Xiao. (2023) Aripiprazole-induced liver injury: a spontaneous reporting database study. Frontiers in Pharmacology 14.
Crossref
Crossref
Kensuke Miyazaki. (2022) Perospirone augmentation of escitalopram in the treatment of an adolescent sophophobia (fear of learning) patient. Neuropsychopharmacology Reports 42:3, pages 374-376.
Crossref
Crossref
Marta Balog, Allison Anderson, Thiago C. Genaro-Mattos, Zeljka Korade & Karoly Mirnics. (2022) Individual and simultaneous treatment with antipsychotic aripiprazole and antidepressant trazodone inhibit sterol biosynthesis in the adult brain. Journal of Lipid Research 63:8, pages 100249.
Crossref
Crossref
Nicolás Meza, Reginald Rees, Camila Micaela Escobar Liquitay, Juan VA Franco, Yanina Sguassero, Katrina Williams, Tamara Pringsheim, Valeria Rojas & Eva Madrid. (2022) Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database of Systematic Reviews 2022:5.
Crossref
Crossref
Alexandra L. Dodd, Sunny Patel & David C. Fipps. (2021) Loxapine-Induced Priapism: A Case Report and Review of the Literature on Antipsychotic-Induced Priapism. Case Reports in Psychiatry 2021, pages 1-5.
Crossref
Crossref
Ankit HalderDr.Dr., Navna PanchamiDr.Dr. & Abhishek DasDr.Dr.. (2021) OLANZAPINE INDUCED AMENORRHEA REVERSED BY SWITCHING TO ARIPIPRAZOLE- A RARE CASE REPORT. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, pages 50-51.
Crossref
Crossref
Cheolmin Shin, Chi-Un Pae, Kyung Phil Kwak, Sang Won Jeon, Hyun-Ghang Jeong, Jong-Woo Kim, Youn Jung Lee, Ashwin A. Patkar & Changsu Han. (2021) Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clinical Psychopharmacology and Neuroscience 19:2, pages 243-253.
Crossref
Crossref
Salah-Eddine El Jabiry, Atif Mansour, Mohammed Barrimi, Bouchra Oneib & Fatima El Ghazouani. (2021) A very rare case of priapism under aripiprazole in a patient followed for bipolar disorder: A CARE-compliant report. Annals of Medicine and Surgery 62, pages 216-218.
Crossref
Crossref
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
418
450.e15
.
Richard G. W. Proudman, Andre S. Pupo & Jillian G. Baker. (2020) The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors. Pharmacology Research & Perspectives 8:4.
Crossref
Crossref
Samantha Alvarez-Herrera, Raúl Escamilla, Oscar Medina-Contreras, Ricardo Saracco, Yvonne Flores, Gabriela Hurtado-Alvarado, José Luis Maldonado-García, Enrique Becerril-Villanueva, Gilberto Pérez-Sánchez & Lenin Pavón. (2020) Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Frontiers in Endocrinology 11.
Crossref
Crossref
R Madan, Vishnu Vardhan, Manaswini Mullapudi & M Vidhyavathi. (2020) Aripiprazole-induced Diplopia: A Rare Case Report. The Journal of Medical Sciences 5:3, pages 73-74.
Crossref
Crossref
Alexander Kiss & Jana Osacka. (2019) Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum. Endocrine Regulations 53:3, pages 165-177.
Crossref
Crossref
Carmen Belmonte, Dolores Ochoa, Manuel Román, Miriam Saiz-Rodríguez, Aneta Wojnicz, Clara Isabel Gómez-Sánchez, Samuel Martín-Vílchez & Francisco Abad-Santos. (2018)
Influence of
CYP2D6
,
CYP3A4
,
CYP3A5
and
ABCB1
Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers
. Basic & Clinical Pharmacology & Toxicology 122:6, pages 596-605.
Crossref
Crossref
Carmen BelmonteDolores OchoaManuel RománTeresa CabaleiroMaria TalegónSergio Daniel Sánchez-RojasFrancisco Abad-Santos. (2016) Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers. Journal of Clinical Psychopharmacology 36:6, pages 608-614.
Crossref
Crossref
Lauren E Hirsch & Tamara Pringsheim. (2016) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2016:6.
Crossref
Crossref
Beatrix Benz, Sandra Unholzer, Alexandra Köppl & Ekkehard Haen. (2016) Therapiealternative mit einem neuen Depotantipsychotikum. NeuroTransmitter 27:5, pages 42-46.
Crossref
Crossref
Yoshikazu Takaesu, Taishiro Kishimoto, Akiko Murakoshi, Nobutada Takahashi & Yuichi Inoue. (2016) Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatry Research 236, pages 71-74.
Crossref
Crossref
Martina Meduri, Giorgia Gregoraci, Valentina Baglivo, Matteo Balestrieri, Miriam Isola & Paolo Brambilla. (2016) A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. Journal of Affective Disorders 191, pages 187-208.
Crossref
Crossref
SatyaK Trivedi, AjishG Mangot & Siddhartha Sinha. (2016) Aripiprazole-induced priapism. Industrial Psychiatry Journal 25:1, pages 119.
Crossref
Crossref
Rahul Singh, Ryan C. Turner, Linda Nguyen, Kartik Motwani, Michelle Swatek & Brandon P. Lucke-Wold. (2016) Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms. Behavioural Neurology 2016, pages 1-14.
Crossref
Crossref
Muharrem Burak Baytunca, Sezen Kose, Burcu Ozbaran & Serpil Erermis. (2015) Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. Pediatrics International 58:1, pages 61-63.
Crossref
Crossref
Joanna M. Wierońska, Stevin H. Zorn, Dario Doller & Andrzej Pilc. (2016) Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. Pharmacology & Therapeutics 157, pages 10-27.
Crossref
Crossref
Eiji Kirino. (2015) Use of aripiprazole for delirium in the elderly: a short review. Psychogeriatrics 15:1, pages 75-84.
Crossref
Crossref
ASIM A. SHAH, AWAIS AFTAB & JOHN COVERDALE. (2014) QTc Prolongation with Antipsychotics. Journal of Psychiatric Practice 20:3, pages 196-206.
Crossref
Crossref
Wen-Yu Hsu, Ting-Gang Chang & Nan-Ying Chiu. (2013) Aripiprazole associated urine retention in a male schizophrenia patient. General Hospital Psychiatry 35:6, pages 680.e11-680.e12.
Crossref
Crossref
T Ishima, M Iyo & K Hashimoto. (2012) Neurite outgrowth mediated by the heat shock protein Hsp90α: a novel target for the antipsychotic drug aripiprazole. Translational Psychiatry 2:10, pages e170-e170.
Crossref
Crossref
Eiji Kirino. (2012) Efficacy and safety of aripiprazole in child and adolescent patients. European Child & Adolescent Psychiatry 21:7, pages 361-368.
Crossref
Crossref
Heidi Ching & Tamara Pringsheim. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Konstantinos N. Fountoulakis, John R. Kelsoe & Hagop Akiskal. (2012) Receptor targets for antidepressant therapy in bipolar disorder: An overview. Journal of Affective Disorders 138:3, pages 222-238.
Crossref
Crossref
Singaravelu Thiyagarajan & Parthipan Sivaraman. (2012) Aripiprazole dose for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Katharina Wenzel-Seifert, Markus Wittmann & Ekkehard Haen. (2011) QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de Pointes. Deutsches Ärzteblatt international.
Crossref
Crossref
A. Carlo Altamura, Marta Serati, Alessandra Albano, Riccardo A. Paoli, Ira D. Glick & Bernardo Dell’Osso. (2011) An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. European Archives of Psychiatry and Clinical Neuroscience 261:7, pages 489-508.
Crossref
Crossref
Tomasz Słowiński, Jacek Stefanowicz, Maciej Dawidowski, Jerzy Kleps, Stanisław Czuczwar, Marta Andres-Mach, Jarogniew J. Łuszczki, Gabriel Nowak, Katarzyna Stachowicz, Bernadeta Szewczyk, Anna Sławińska, Aleksander P. Mazurek, Andrzej Mazurek, Franciszek Pluciński, Irena Wolska & Franciszek Herold. (2011) Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. European Journal of Medicinal Chemistry 46:9, pages 4474-4488.
Crossref
Crossref
Heidi Ching & Tamara Pringsheim. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Martin A. Katzman. (2011) Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. Journal of Affective Disorders 128, pages S11-S20.
Crossref
Crossref
Stanley Fahn, Joseph Jankovic & Mark Hallett. 2011. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
350
379
.
Donald J. AbrahamRichard B. Mailman & Kent E. Vrana. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
14
.
Ian P. Holmes, Richard J. Blunt, Olivier E. Lorthioir, Stephen M. Blowers, Andy Gribble, Andrew H. Payne, Ian G. Stansfield, Martyn Wood, Patrick M. Woollard, Charlie Reavill, Claire M. Howes, Fabrizio Micheli, Romano Di Fabio, Daniele Donati, Silvia Terreni, Dieter Hamprecht, Luca Arista, Angela Worby & Steve P. Watson. (2010) The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure. Bioorganic & Medicinal Chemistry Letters 20:6, pages 2013-2016.
Crossref
Crossref
Emmanuel Stip & Valérie Tourjman. (2010) Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clinical Therapeutics 32, pages S3-S20.
Crossref
Crossref
Konstantinos N Fountoulakis & Eduard Vieta. (2009) Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Annals of General Psychiatry 8:1.
Crossref
Crossref
Min-Soo Lee & Hun Soo Chang. 2009. Schizophrenia. Schizophrenia
218
230
.
Samir Kumar Praharaj, Amlan K. Jana & Vinod Kumar Sinha. (2009) Aripiprazole-induced sialorrhea. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:2, pages 384-385.
Crossref
Crossref
Leo Bastiaens. (2009) Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole. Clinical Medicine. Therapeutics 1, pages CMT.S2238.
Crossref
Crossref
Mary Weber, Afshin M. Gutierrez & Mina Mohammadi. (2009) The Risks and Benefits of Switching Antipsychotics: A Case Study Approach. Perspectives in Psychiatric Care 45:1, pages 54-61.
Crossref
Crossref
Brett Y. Lu, Chandra E. Cullen, Carla E. Eide, Cynthia C. Williams & William J. Apfeldorf. (2008) Antidepressant-Induced Sweating Alleviated by Aripiprazole. Journal of Clinical Psychopharmacology 28:6, pages 710-711.
Crossref
Crossref
Andrea Sandoz, Matteo LoPiccolo, Daniel Kusnir & Francisco A. Tausk. (2008) A clinical paradigm of delusions of parasitosis. Journal of the American Academy of Dermatology 59:4, pages 698-704.
Crossref
Crossref
Biswaranjan Mishra, Samir Kumar Praharaj, Ravi Prakash & Vinod Kumar Sinha. (2008) Aripiprazole-induced acneiform eruption. General Hospital Psychiatry 30:5, pages 479-481.
Crossref
Crossref
M. Dominic Beer, Stephen M. Pereira & Carol PatonChike I. Okocha. 2009. Psychiatric Intensive Care. Psychiatric Intensive Care
50
73
.
M B Cope, P Jumbo-Lucioni, R G Walton, R A Kesterson, D B Allison & T R Nagy. (2007) No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs. International Journal of Obesity 31:6, pages 1014-1022.
Crossref
Crossref
J. Wolf & U. Fiedler. (2007) Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. Journal of Clinical Pharmacy and Therapeutics 32:2, pages 197-198.
Crossref
Crossref
Matthew A. Menza, Roseanne D. Dobkin & Humberto Marin. (2007) An Open-Label Trial of Aripiprazole Augmentation for Treatment-Resistant Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology 22:2, pages 207-210.
Crossref
Crossref
Antonio Párraga, Jörg Holenz & Helmut Buschmann. 2007. Antidepressants, Antipsychotics, Anxiolytics. Antidepressants, Antipsychotics, Anxiolytics
491
616
.
Peter M Haddad & Sonu G Sharma. (2007) Adverse Effects of Atypical Antipsychotics. CNS Drugs 21:11, pages 911-936.
Crossref
Crossref
Eugenia Rota, Giovanni Bergesio, Elisabetta Dettoni & Claudio M. Demicheli. (2007) Pisa syndrome during aripiprazole treatment: A case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31:1, pages 286-287.
Crossref
Crossref
Shih-Jen Tsai. (2007) TrkB partial agonists: Potential treatment strategy for major depression. Medical Hypotheses 68:3, pages 674-676.
Crossref
Crossref
Zoe Clarke. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
Stanley Fahn, Joseph Jankovic, Mark Hallett & Peter Jenner. 2007. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
409
442
.
Marci L. Chew, Benoit H. Mulsant, Bruce G. Pollock, Mark E. Lehman, Andrew Greenspan, Margaret A. Kirshner, Robert R. Bies, Shitij Kapur & Georges Gharabawi. (2006) A model of anticholinergic activity of atypical antipsychotic medications. Schizophrenia Research 88:1-3, pages 63-72.
Crossref
Crossref
Alberto SalmoiraghiMahesh Odiyoor. (2006) A case of Aripiprazole and extra pyramidal side effects. Journal of Psychopharmacology 20:4, pages 592-593.
Crossref
Crossref
Rajiv Tandon, Ronald N. Marcus, Elyse G. Stock, Linda C. Riera, Dusan Kostic, Miranda Pans, Robert D. McQuade, Margaretta Nyilas, Taro Iwamoto & David T. Crandall. (2006) A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Research 84:1, pages 77-89.
Crossref
Crossref
Patricia A Marken & Ronald W Pies. (2016) Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles. Annals of Pharmacotherapy 40:2, pages 276-285.
Crossref
Crossref
Peter J. Weiden. (2005) Switching antipsychotics: an updated review with a focus on quetiapine. Journal of Psychopharmacology 20:1, pages 104-118.
Crossref
Crossref
&NA;. (2005) Consider the advantages/disadvantages of different switching methods when changing atypical antipsychotics. Drugs & Therapy Perspectives 21:12, pages 20-23.
Crossref
Crossref
David L Dunner. (2005) Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disorders 7:4, pages 307-325.
Crossref
Crossref
Eduard Vieta & Jose M Goikolea. (2005) Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorders 7:s4, pages 21-33.
Crossref
Crossref
Thomas P. Beresford, Lori Clapp, Brandon Martin, John L. Wiberg, Julie Alfers & Henry F. Beresford. (2005) Aripiprazole in Schizophrenia With Cocaine Dependence. Journal of Clinical Psychopharmacology 25:4, pages 363-366.
Crossref
Crossref
Gara L. Coffey, Sheila R. Botts & Jose de Leon. (2005) High vulnerability to acute dystonic reactions: A case of antipsychotic exposure and uncontrolled seizure activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:5, pages 770-774.
Crossref
Crossref
Joseph A De Soto, Aneela Kazi, Alejandro Rivera & AB Wilson Muhammad. (2016) A Case Study: Treatment of Refractory Schizoaffective Disorder with Aripiprazole. Journal of Pharmacy Technology 21:3, pages 150-153.
Crossref
Crossref
G. S. Malhi, M. Berk, M. Bourin, B. Ivanovski, S. Dodd, J. Lagopoulos & P. B. Mitchell. (2005) Atypical mood stabilizers: a 'typical' role for atypical antipsychotics. Acta Psychiatrica Scandinavica 111:s426, pages 29-38.
Crossref
Crossref
David E. Adson, Matt G. Kushner & Tamara A. Fahnhorst. (2005) Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. Journal of Affective Disorders 86:1, pages 99-104.
Crossref
Crossref
Monika Edlinger, Susanne Baumgartner, Nadja Eltanaihi-Furtm??ller, Martina Hummer & W Wolfgang Fleischhacker. (2005) Switching Between Second-Generation Antipsychotics. CNS Drugs 19:1, pages 27-42.
Crossref
Crossref
Karine Titier, Pierre-Olivier Girodet, H??l??ne Verdoux, Mathieu Molimard, Bernard B??gaud, Wilhelm Haverkamp, Malcolm Lader & Nicholas Moore. (2005) Atypical Antipsychotics. Drug Safety 28:1, pages 35-51.
Crossref
Crossref
Bollikonda Satyanarayana, Yasareni Sumalatha, Sythana Suresh Kumar, Sundaram Venkatraman, Ghanta Mahesh Reddy & Padi Pratap Reddy. (2005) SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE. Heterocyclic Communications 11:6, pages 485-490.
Crossref
Crossref
K Ranga Rama Krishnan. (2005) Psychiatric and Medical Comorbidities of Bipolar Disorder. Psychosomatic Medicine 67:1, pages 1-8.
Crossref
Crossref
Shih-Jen Tsai. (2005) The novel atypical antipsychotic aripiprazole as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Medical Hypotheses 65:3, pages 633-634.
Crossref
Crossref
Marilyn A Davies, Douglas J. Sheffler & Bryan L. Roth. (2006) Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews 10:4, pages 317-336.
Crossref
Crossref
David A. Fishbain, R. B. Cutler, John Lewis, Brandly Cole, R. Steele Rosomoff & H. L. Rosomoff. (2004) Do The Second-Generation “Atypical Neuroleptics” Have Analgesic Properties? A Structured Evidence-Based Review: Table 1. Pain Medicine 5:4, pages 359-365.
Crossref
Crossref
Hua Jin, Jonathan M. Meyer & Dilip V. Jeste. (2004) Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 71:2-3, pages 195-212.
Crossref
Crossref
Jonathan M Meyer & Carol E Koro. (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 70:1, pages 1-17.
Crossref
Crossref
David E. Adson. (2004) Considering long-term outcome and tolerability in the treatment of bipolar disorder. Current Psychosis & Therapeutics Reports 2:3, pages 121-127.
Crossref
Crossref
Christoph Hiemke, Aleksandra Dragicevic, Gerhard Gründer, Sebastian Hätter, Julia Sachse, Ingo Vernaleken & Matthias J. Müller. (2004) Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring 26:2, pages 156-160.
Crossref
Crossref
Peter M Haddad & Angelika Wieck. (2004) Antipsychotic-Induced Hyperprolactinaemia. Drugs 64:20, pages 2291-2314.
Crossref
Crossref
S. Tardieu, J. Micallef, S. Gentile & O. Blin. (2003) Weight gain profiles of new anti-psychotics: public health consequences. Obesity Reviews 4:3, pages 129-138.
Crossref
Crossref
David A Shapiro, Sean Renock, Elaine Arrington, Louis A Chiodo, Li-Xin Liu, David R Sibley, Bryan L Roth & Richard Mailman. (2003) Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology 28:8, pages 1400-1411.
Crossref
Crossref
Martha Sajatovic. (2003) Treatment for mood and anxiety disorders: Quetiapine and aripiprazole. Current Psychiatry Reports 5:4, pages 320-326.
Crossref
Crossref
Cécile Boyer-Joubert, Edwige Lorthiois & François Moreau. 2003.
347
374
.